KR880007507A - 크로만 유도체 - Google Patents

크로만 유도체 Download PDF

Info

Publication number
KR880007507A
KR880007507A KR870014730A KR870014730A KR880007507A KR 880007507 A KR880007507 A KR 880007507A KR 870014730 A KR870014730 A KR 870014730A KR 870014730 A KR870014730 A KR 870014730A KR 880007507 A KR880007507 A KR 880007507A
Authority
KR
South Korea
Prior art keywords
formula
compound
dimethyl
carbon atoms
pyridone
Prior art date
Application number
KR870014730A
Other languages
English (en)
Other versions
KR960004828B1 (ko
Inventor
하우슬러 귄터
게리커 롤프
브리지거 한스
바움가르드 만프레트
루에스 인거
드 페이어 약퀘스
베르그만 롤프
Original Assignee
브리지테 노우만, 위르겐 헤우만
메르크 파텐트 게젤샤프트 미트 베슈랭크터 하프퉁
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25850767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR880007507(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 브리지테 노우만, 위르겐 헤우만, 메르크 파텐트 게젤샤프트 미트 베슈랭크터 하프퉁 filed Critical 브리지테 노우만, 위르겐 헤우만
Publication of KR880007507A publication Critical patent/KR880007507A/ko
Application granted granted Critical
Publication of KR960004828B1 publication Critical patent/KR960004828B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음.

Description

크로만 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 일반식(I)의 크로만 유도체 및 이들 염.
    상기식에서, R1은 A이고, R2은 H 또는 A이고, R1및 R2는 함께 또한 탄소수 3 내지 6의 알킬렌이고, R3는 OH 또는 OAc이고, R4는 H이고, R3및 R4는 함께 단일 결합이고, R5는 비치환 또는 A, F, Cl, Br, I, OH, OA, OAc, NO2, NH2, AcNH, HOOC 및/또는 AOOC에 의해 일치환 또는 이치환된 1H-2-피리돈-1-일, 1H-6-피리다지논-1一일, 1H-2-피리미디논-1-일, 1H-6-피리미디논-1-일, 1H-2-피리지논-1-일, 1H-2-피라지논-1-일 또는 1H-2-티오피리돈-1-일 라디칼이고, 이들 래디칼은 부분적으로 수소화 할 수도 있으며, R6및 R7은 각기 H, A, HO, AO, CHO, ACO, ACS. HOOC, AOOC, AO-CS, ACOO, A-CS-O, 탄소수 1 내지 6의 히드록시알킬, 탄소수 1 내지 6의 머캅토알킬, NO2, NH2, NHA, NA2, CN, F, Cl, Br, I, CF3, ASO, ASO2, AO-SO, AO-SO2, AcNH, AO-CO-NH, H2NSO, HANSO, A2NSO, H2NSO2, HANSO2A2NSO2, H2NCO, HANCO, A2NCO, H2NCS, HANCS, A2NCS, ASONH, ASO2NH, AOSONH, AOSO2NH, ACO-알킬, 니트로알킬, 시아노알킬, A-C(=NOH) 또는 A-C(=NNH2)이고, 여기에서, A는 탄소수 1 내지 6의 알킬이고, 알킬은 탄소수 1 내지 6의 알킬렌이고, Ac는 탄소수 1 내지 8의 알카노일 또는 탄소수 7 내지 11의 아로일이다.
  2. a) 2,2-디메틸-4-(1H-2-피리돈-(-일)-6-시아노-2H-크로멘 ; b) 2,2-디메틸-4-(1H-2-피리돈-1-일)-6-시아노크로만-3-올 ; c) 2,2-디메틸-4-(1H-2-피리돈-1-일)-6-니트로-2H-크로멘 ; d) 2,2-디메틸-4-(1H-2-피리돈-1-일)-6-니트로크로만-3-올 ; e) 2,2-디메틸-4-(1H-4-히드록시-1-일)-6-시아노크로만-3-올 ; f) 2,2-디메틸-4-(1H-2-피라지논-1-일)-6-시아노-2H-크로멘 ; g) 2,2-디메틸-4-(1H-2-피라지논-1-일)-6-시아노크로만-3-올.
  3. 일반식(II)의 3,4-에폭시크로만을 일반식(III)의 화합물 또는 이의 반응 유도체와 반응시키고/거나, R3은 OH이고 R4는 H인 일반식(I)의 화합물을 탈수시키고/거나, 일반식(I)의 화합물중의 1종 이상의 라디칼 R3, R5, R6및/또는 R7는 다른 라디칼 R3, R5, R6및/또는 R7로 전환시키고/거나 일반식(I)의 염기성 화합물은 산으로 처리하여 이의 산 부가염증 하나로 전환시키는 것을 특징으로 하는, 제1항에 따른 일반식(I)의 크로만 유도체의 제조방법.
    상기식에서, R1, R2, R5, R6및 R7은 일반식(I)에서 정의된 바와 같다.
  4. 일반식(I)의 화합물 및/또는 이의 약리학적으로 허용가능한 염중 하나를 적어도 1종의 고체, 액체 또는 반-액체 부형제 또는 보조제와 함께 그리고 필요하다면, 1종 이상의 다른 활성 화합물과 배합하여 적합한 투약형태로 만드는 것을 특징으로 하는 약제학적 제형의 제조방법.
  5. 적어도 1종의 일반식(I)의 화합물 및/또는 이의 생리학적으로 허용가능한 염중 하나를 함유하는 것을 특징으로 하는 약제학적 제형.
  6. 질병 퇴치를 위한 일반식(I)의 화합물.
  7. 약품의 제조를 위한 일반식(I)의 화합물의 용도.
  8. 질병퇴치에 있어서의 일반식(I)의 화합물의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870014730A 1986-12-23 1987-12-22 크로만 유도체 및 이의 제조방법 KR960004828B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DEP3644094.9 1986-12-23
DE3644094 1986-12-23
DE3644094.9 1986-12-23
DEP3726261.0 1987-08-07
DE3726261.0 1987-08-07
DE19873726261 DE3726261A1 (de) 1986-12-23 1987-08-07 Chromanderivate

Publications (2)

Publication Number Publication Date
KR880007507A true KR880007507A (ko) 1988-08-27
KR960004828B1 KR960004828B1 (ko) 1996-04-16

Family

ID=25850767

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870014730A KR960004828B1 (ko) 1986-12-23 1987-12-22 크로만 유도체 및 이의 제조방법

Country Status (7)

Country Link
EP (1) EP0273262A3 (ko)
JP (1) JP2523343B2 (ko)
KR (1) KR960004828B1 (ko)
AU (1) AU604809B2 (ko)
CA (1) CA1340960C (ko)
DE (1) DE3726261A1 (ko)
HU (1) HU207728B (ko)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3820506A1 (de) * 1988-06-16 1989-12-21 Merck Patent Gmbh -n-heterocyclisch substituierte chromanderivate und ihre verwendung als arzneimittel
DE3835011A1 (de) * 1988-10-14 1990-04-19 Merck Patent Gmbh Chromanderivate
US5387587A (en) * 1986-12-23 1995-02-07 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
DE3881714D1 (de) * 1987-02-04 1993-07-22 Hoechst Ag Alkylsubstituierte n-benzopyranyllactame, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen.
IL86798A (en) * 1987-06-23 1992-12-01 Sanofi Sa 2,2-dimethylchroman-3-ol derivatives, their preparation and pharmaceutical compositions containing them
US5284838A (en) * 1987-06-23 1994-02-08 Elf Sanofi Use of 2,2-dimethylchroman-3-ol derivatives in the treatment of asthma
AU618007B2 (en) * 1987-06-23 1991-12-12 Sanofi 2,2-dimethylchroman-3-ol derivatives, process for their preparation and pharmaceutical compositions in which they are present
DE3732146A1 (de) * 1987-09-24 1989-04-06 Merck Patent Gmbh Azachromanderivate
FR2621587B1 (fr) * 1987-10-12 1990-02-09 Sanofi Sa Derives du dimethyl-2,2 chromene, procede pour leur preparation et composition pharmaceutiques les contenant
GB8800199D0 (en) * 1988-01-06 1988-02-10 Beecham Group Plc Pharmaceutical preparation
DE3811017A1 (de) * 1988-03-31 1989-10-19 Hoechst Ag Ungesaettigte n-benzopyranyllactame
US5021432A (en) * 1988-04-26 1991-06-04 Yoshitomi Pharmaceutical Industries, Ltd. Benzopyran compound and its pharmaceutical use
AU628331B2 (en) * 1988-05-06 1992-09-17 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
WO1989010925A1 (en) * 1988-05-09 1989-11-16 Beecham Group Plc Novel compounds and treatment
US5254557A (en) * 1988-05-09 1993-10-19 Beecham Group P.L.C. Compound and treatment
EP0346724A1 (de) * 1988-06-16 1989-12-20 MERCK PATENT GmbH Chromanderivate
DE3823533A1 (de) * 1988-07-12 1990-02-08 Beiersdorf Ag Substituierte 4-heterocyclyl-2h-benzo(b)pyrane, verfahren und 4-hydroxy-3-brom-, 3,4-oxiranyl-3,4-dehydro-2h-benzo(b)pyrane als zwischenprodukte zu ihrer herstellung, sowie sie enthaltende pharmazeutsche praeparate
DE3827532A1 (de) * 1988-08-13 1990-03-01 Hoechst Ag 6-aroyl-substituierte 3,4-dihydro-2h-benzopyrane, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen
DE3837809A1 (de) * 1988-11-08 1990-05-10 Merck Patent Gmbh Tetralinderivate
FR2639227A1 (fr) * 1988-11-23 1990-05-25 Sanofi Sa Utilisation de derives du chromane pour le traitement des etats depressifs
US5072006A (en) * 1988-12-09 1991-12-10 Recherche Syntex France S.A. Novel benzopyranylpyrrolinone derivatives
EP0633256A1 (en) * 1988-12-13 1995-01-11 Beecham Group Plc Benzopyran and related compounds
FR2641784B1 (fr) * 1988-12-26 1994-02-25 Sanofi Procede de preparation de derives du chromanne et intermediaires de synthese
DE3904496A1 (de) * 1989-02-15 1990-08-16 Merck Patent Gmbh Verfahren zur enantiomerentrennung eines benzopyranderivats
US5162553A (en) * 1989-03-03 1992-11-10 Yoshitomi Pharmaceutical Industries, Ltd. Processes for preparing optically active 3,4-dihydro-3,4-epoxy-2H-1-benzopyran compounds and intermediates therefor
US5066816A (en) * 1989-03-03 1991-11-19 Yoshitomi Pharmaceutical Industries, Ltd. Processes for preparing optically active 3,4-dihydro-3,4-epoxy-2h-1-benzopyran compounds and intermediates therefor
FR2645021A1 (fr) * 1989-03-30 1990-10-05 Sanofi Sa Utilisation d'un agoniste potassique dans le traitement du glaucome
DE3915236A1 (de) * 1989-05-10 1990-11-15 Merck Patent Gmbh Pharmazeutische zubereitung
DE3918041A1 (de) * 1989-06-02 1990-12-06 Merck Patent Gmbh Chromanderivate
DE3922392A1 (de) 1989-07-07 1991-01-17 Merck Patent Gmbh Chromanderivate
DE3923839A1 (de) * 1989-07-19 1991-01-31 Beiersdorf Ag Benzopyran-derivate, verfahren zu ihrer herstellung und ihre verwendung sowie die verbindungen enthaltende zubereitungen
DE3924417A1 (de) * 1989-07-24 1991-01-31 Merck Patent Gmbh Chromanderivate
DE3926001A1 (de) * 1989-08-05 1991-02-07 Merck Patent Gmbh Chromanderivate
WO1991009031A1 (en) * 1989-12-11 1991-06-27 Beecham Group Plc Trifluoromethyl substituted compounds and a pharmaceutical composition
DE4010097A1 (de) * 1990-03-29 1991-10-02 Basf Ag Ungesaettigte n-benzoxodiazolopyranyllactame, ihre herstellung und verwendung
US5254578A (en) * 1990-10-24 1993-10-19 Sankyo Company, Limited Benzopyran derivatives having anti-hypertensive and vasodilatory activity and their therapeutic use
FR2698873B1 (fr) 1992-12-07 1995-02-24 Lipha Benzocycloheptènes, benzoxépines et benzothiépines activateurs des canaux potassiques, procédé de préparation, composition pharmaceutique les contenant.
EP1940516A2 (en) * 2005-09-01 2008-07-09 Janssen Pharmaceutica, N.V. Benzopyran and pyranopyridine derivatives as potassium channel openers
JP2009509928A (ja) 2005-09-01 2009-03-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ カリウムチャンネル開口剤としての新規ベンゾピラン誘導体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3274350D1 (en) * 1981-09-25 1987-01-08 Beecham Group Plc Pharmaceutically active benzopyran compounds
DE3368629D1 (en) * 1982-04-28 1987-02-05 Beecham Group Plc Novel chromenes and chromans
EP0107423B1 (en) * 1982-10-19 1986-07-23 Beecham Group Plc Novel chromans and chromenes
GB8308064D0 (en) * 1983-03-24 1983-05-05 Beecham Group Plc Active compounds
GB8419516D0 (en) * 1984-07-31 1984-09-05 Beecham Group Plc Treatment
GB8625185D0 (en) * 1986-10-21 1986-11-26 Beecham Group Plc Active compounds
DE3835011A1 (de) * 1988-10-14 1990-04-19 Merck Patent Gmbh Chromanderivate
AU618007B2 (en) * 1987-06-23 1991-12-12 Sanofi 2,2-dimethylchroman-3-ol derivatives, process for their preparation and pharmaceutical compositions in which they are present
IL86798A (en) * 1987-06-23 1992-12-01 Sanofi Sa 2,2-dimethylchroman-3-ol derivatives, their preparation and pharmaceutical compositions containing them
FR2621587B1 (fr) * 1987-10-12 1990-02-09 Sanofi Sa Derives du dimethyl-2,2 chromene, procede pour leur preparation et composition pharmaceutiques les contenant
EP0322361A3 (de) * 1987-12-23 1990-01-24 Ciba-Geigy Ag Weitere hydrierte 1-Benzooxacycloalkylpyridincarbonsäureverbindungen
DE3811017A1 (de) * 1988-03-31 1989-10-19 Hoechst Ag Ungesaettigte n-benzopyranyllactame

Also Published As

Publication number Publication date
EP0273262A2 (de) 1988-07-06
JP2523343B2 (ja) 1996-08-07
CA1340960C (en) 2000-04-18
AU604809B2 (en) 1991-01-03
HU207728B (en) 1993-05-28
JPS63170376A (ja) 1988-07-14
HUT48621A (en) 1989-06-28
AU8268987A (en) 1988-06-23
KR960004828B1 (ko) 1996-04-16
EP0273262A3 (de) 1989-12-06
DE3726261A1 (de) 1988-07-07

Similar Documents

Publication Publication Date Title
KR880007507A (ko) 크로만 유도체
KR890017246A (ko) 크로만 유도체
KR890002060A (ko) 옥사졸리디논 화합물
HUT43786A (en) Process for production of medical compounds with increased giving down of the active substance
KR880006193A (ko) 피페리딘 화합물 및 그의 제조 및 용도
KR910000711A (ko) 크로만 유도체
KR900006326A (ko) 크로만 유도체
KR900007798A (ko) 테트랄린 유도체
KR910000713A (ko) 크로만 유도체
KR910004602A (ko) 크로만 유도체
KR870007118A (ko) 광학적으로 순수한 화합물 및 그의 제조 방법
PT69618A (de) Neue imidazolderivate verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praparate
KR910002845A (ko) 크로만 유도체
KR910002842A (ko) 크로만 유도체
ATE41772T1 (de) Polymethoxybenzyl-piperazin-derivate, verfahren zu ihrer herstellung und diese derivate enthaltende pharmazeutische zusammensetzungen.
KR940003953A (ko) 1. 4-벤조디옥산 유도체
KR920012073A (ko) 크로만 유도체
ATE62908T1 (de) Neue derivate von 4,5-dihydro-oxazolen, verfahren zu ihrer herstellung und ihre verwendung.
KR910021400A (ko) 옥사졸리디논
FR2536751B1 (fr) Nouveaux derives de tricyclophosphazenes, procede pour leur preparation et leur application en tant que medicament
ATE2423T1 (de) 1-acyloxyphenyl-1,2-diphenylalken-derivate, verfahren zu deren herstellung und eine diese derivate enthaltende pharmazeutische zusammensetzung.
KR890003692A (ko) 1.2.5.6- 테트라히드로피리딘-3-카르복스알데히드의 옥심유도체, 이들의 제조방법, 약제로서의 이들의 용도 및 이들을 함유하는 조성물
KR880004810A (ko) 소화성 궤양 치료제
KR910007907A (ko) 크로만 유도체
KR910002456A (ko) 당뇨병 치료용 제약 조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20000408

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee